Abstract Number: 1029 • ACR Convergence 2024
An Analysis of Osteoporosis Screening in Males vs. Females Across Lehigh Valley Health Network
Background/Purpose: Osteoporosis is a widely recognized disease of the bone where bone mineral density is decreased leading to increased risk for fracture. Bone mineral density…Abstract Number: 2118 • ACR Convergence 2024
Cytotoxic T Lymphocyte Antigen-4 Improves Osteoporosis in Patient with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is recognized as a risk factor for osteoporosis. Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) acts as an inhibitory regulator post-T cell activation,…Abstract Number: 2140 • ACR Convergence 2024
Frailty Is Associated with Lower Bone Mineral Density in US Veterans with Rheumatoid Arthritis
Background/Purpose: Frailty represents a state of increased vulnerability to poor outcomes after physiologic stressors, and occurs at higher rates and younger ages in RA. Frailty…Abstract Number: 1033 • ACR Convergence 2024
Osteoporosis and Cardiovascular Disease: Mortality Trends Among Adults in the United States from 1999 to 2020
Background/Purpose: Osteoporosis and cardiovascular disease (CVD) represent significant public health concerns. This study investigates the trends and demographic disparities in mortality due to osteoporosis and…Abstract Number: 2120 • ACR Convergence 2024
EvaluationofBone Mineral Densityand Trabecular Bone Score in JuvenileSystemicLupusErythematosusPatientsUsing Dual-Energy X-rayAbsorptiometry
Background/Purpose: Juvenile Systemic Lupus Erythematosus (jSLE) is a multisystem inflammatory disease associated with bone mass loss. This loss can be evaluated by using the bone…Abstract Number: 2141 • ACR Convergence 2024
Glucocorticoid Therapy-Associated Bone Fractures Are Associated with Osteoporosis Underscreening in Patients with Rheumatoid Arthritis
Background/Purpose: The majority of bone loss happens within 6 months of glucocorticoid treatment. Per the 2022 American College of Rheumatology (ACR) Glucocorticoid-Induced Osteoporosis Guidelines it…Abstract Number: 1055 • ACR Convergence 2024
Impact of Provider Billing vs. Pharmacy Dispensation for Romosozumab Treatment Discontinuation Among U.S. Postmenopausal Women with Osteoporosis
Background/Purpose: Medicare Part B drug expenditures have increased due to the rising use of expensive specialty drugs like provider-administered biologics. These medications can also be…Abstract Number: 2122 • ACR Convergence 2024
Rheum for Improvement: Screening and Treatment of Glucocorticoid Induced Osteoporosis
Background/Purpose: Glucocorticoid induced osteoporosis (GIOP) accelerates bone loss and increases fracture risk. We evaluated GIOP screening and prescribing patterns in our Veterans Affairs (VA)-based academic…Abstract Number: 2142 • ACR Convergence 2024
Comparison of Bone Mineral Density at the Distal Radius, Hip, and Lumbar Spine in Female Patients Undergoing Surgery for Proximal Femur or Distal Radius Fractures: Implications for Osteoporosis Diagnosis
Background/Purpose: Osteoporosis is often diagnosed based on bone mineral density (BMD) measurements at the hip or lumbar spine. However, our previous study reported that 38%…Abstract Number: 1061 • ACR Convergence 2024
Utilization of Electronic Health Record System to Improve Glucocorticoid Induced Osteoporosis Screening and Treatment
Background/Purpose: Osteoporosis is the most common bone disease leading to fragility fractures associated with significant morbidity and increased mortality (1). Glucocorticoids (GC) are widely used…Abstract Number: 2123 • ACR Convergence 2024
Epidemiology of Bone Health and Fracture in Gout Patients
Background/Purpose: Gout is an erosive arthropathy, and gout patients have been shown to have a higher occurrence of osteoporosis and fracture. This study evaluated bone…Abstract Number: 2143 • ACR Convergence 2024
Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population
Background/Purpose: Excluding clinical trials, there is limited evidence on the effect of 12 months of romosozumab treatment on increasing bone mineral density (BMD) in real-world…Abstract Number: 1620 • ACR Convergence 2023
Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab
Background/Purpose: Romosozumab (romo) and denosumab (dmab) are recommended for postmenopausal women with osteoporosis (OP) at high risk of fracture. The U.S. prescribing information includes a…Abstract Number: 2009 • ACR Convergence 2023
Screening and Treatment of Low Bone Mineral Density in Allogeneic Hematopoietic Cell Transplant Patients
Background/Purpose: Bone mineral density (BMD) loss and fracture are important causes of increased morbidity following allogeneic hematopoietic stem cell transplant (allo-HCT).Recent societal recommendations support screeningDual…Abstract Number: 2530 • ACR Convergence 2023
Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center
Background/Purpose: Osteoporotic fractures are a well-known complication in LT recipients, significantly impacting their quality of life. Specific risk factors for these fractures in LT recipients…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 20
- Next Page »